

Interim Report

MeVis Medical Solutions AG H1-2024/2025



MeVis

TABLE OF CONTENTS

FOREWORD BY THE CEO.....	2
THE MEVIS SHARE.....	3
INTERIM MANAGEMENT REPORT H1 2024/2025.....	4
Preliminary remark.....	4
Foundations of the company.....	4
Organization.....	4
Brief overview of business activities.....	4
Economic report.....	5
Business performance	5
Earnings situation	5
Net assets and financial position.....	6
Opportunity and risk report	6
Forecast report	6
BALANCE SHEET	7
PROFIT AND LOSS ACCOUNT	9
NOTES	10
Basic information	10
General information	10
Accounting and valuation methods	10
Selected notes to the balance sheet and income statement.....	10
1. Receivables and other assets.....	10
2. Provisions.....	10
3. Liabilities.....	11
4. Accruals and deferred income	11
5. Sales revenue.....	11
6. Other operating income	11
7. Personnel expenses	11
8. Other operating expenses	11
9. Relationships with related parties	11
Supplementary report	12
ASSURANCE OF THE LEGAL REPRESENTATIVE	13
DISCLAIMER	14

FOREWORD BY THE CEO

Dear readers,

In the first half of the year, revenue was slightly below our expectations overall: the Company's revenue amounted to € 8,438 thousand (previous year: € 8,774 thousand). Of this figure, 22% (previous year: 27%) is attributable to the sale of licenses, 34% (previous year: 35%) to maintenance revenue and 44% (previous year: 38%) to other revenue, which includes services for and recharges to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) fell from € 2,092 thousand to € 1,853 thousand, which corresponds to an EBIT margin of 22%, mainly due to lower sales compared to the previous year, increased other operating income and higher personnel expenses.

The deterioration in license sales compared to the same period in the previous year is due to the lack of license sales in the lung screening segment and weaker license sales in mammography. We had anticipated a slight decline in license sales in mammography, but in addition there have been isolated difficulties with deliveries at Hologic, meaning that our assumptions for the first half of the year have not yet been met. The other sales with Hologic, maintenance and development services, are slightly better than budgeted.

Sales development in the lung cancer screening solutions segment is not yet in line with our expectations. License sales are still below the previous year and our original targets. However, the opportunities to be seized for our lung cancer screening solutions are increasing, as more and more countries have recognized the need for early detection and are launching tenders for their nationwide lung cancer screening programmes, in which we are participating, such as Canada and Australia. At the same time, however, we are also noticing that more and more medical technology companies are focusing on solutions for early lung cancer detection and launching products to the market, which means that competition in this area is increasing. We will strengthen our marketing and sales activities in this area and promote our products positively.

The area of liver diagnostics and liver surgery solutions continued to develop very positively in the first half of 2024/2025. We are experiencing increasing demand for both MeVis' own software application MeVis LiverSuite and MeVis' own service MeVis Distant Services. In addition to the US market, which is very important to us, we will increasingly expand our activities here to large markets such as the Middle East and India.

General maintenance revenue at MeVis declined slightly compared to the same period of the previous year. Fortunately, other revenue, in particular the development projects with Varex and Varian, developed positively.

At this point in time, we are sticking to our forecast: stable to slightly growing sales in the range of € 17.0 million to € 17.5 million are expected for the 2024/2025 financial year. In addition to stable sales with the customer Hologic, sales in the lung and liver segments are expected to increase slightly. We expect development services to remain stable. We expect earnings before interest and taxes (EBIT) for the financial year 2024/2025 to be between € 3.5 million and € 4.0 million, assuming a stable exchange rate of 1.12 USD/EUR. The forecast stability or slight increase in sales and the disproportionately low increase in personnel costs are the main drivers of the positive EBIT outlook. The Executive Board will regularly review its expectations over the course of the 2024/2025 financial year on the basis of current business developments.



Marcus Kirchhoff
CEO

THE MEVIS SHARE

AS OF March 31, 2025	
ISIN / WKN / Ticker Symbol	DE000A0LBFE4 / A0LBFE / M3V
Industry classification	Software / Medical technology
Share capital	€ 1,820,000.00
Number of shares	1,820,000
Last price determination on Sep. 30, 2024	€ 23.00
Last price determination on Mar. 31, 2025	€ 26.00
Highest/lowest price in 2024/2025	€ 26.60 / € 23.40
Market capitalization	€ 47.320 million
General Standard (Regulated Market)	Frankfurt and Xetra
Regulated unofficial market	Berlin, Düsseldorf, Munich, Stuttgart
Indices	CDAX, General All-Share, DAXsector All Software

SHARE PRICE PERFORMANCE

From October 1, 2024 to March 31, 2025, the MeVis Medical Solutions AG share price averaged around € 25.00. At the beginning of the fiscal year, the share was listed at € 23.40 and closed at € 26.00 in Xetra trading at the end of March. During the first half of fiscal year 2024/2025, the share price reached a high of € 26.60 and a low of € 23.40 in Xetra trading. Compared to € 25.00 at the end of March 31, 2024, the value of the MeVis share has risen slightly by 4% in twelve months. As at the reporting date of March 31, 2025, the market capitalization thus amounted to approximately € 47 million, taking into account 1,820,000 shares in circulation.

SHAREHOLDER STRUCTURE AS AT MARCH 31, 2025

As of the balance sheet date, 73.66% of the total share capital of MeVis Medical Solutions AG was held by Varex Imaging Deutschland AG, an indirect subsidiary of Varex Imaging Corporation, Salt Lake City, Utah, USA. According to the shareholder notifications received by us, another institutional shareholder is HANSAINVEST Hanseatische Investment-GmbH, which holds approx. 12.57% of the total share capital of MeVis Medical Solutions AG. This means that around 13.77% of the shares are in free float.

COMPENSATION PAYMENT

The domination and profit and loss transfer agreement between Varex Imaging Deutschland AG and MeVis Medical Solutions AG obliges Varex Imaging Deutschland AG to pay the outside shareholders a recurring cash payment ("compensation payment") for each full financial year for the duration of this agreement. This amounts to € 1.13 (gross) or € 0.95 (net) per share for each full financial year.

INTERIM MANAGEMENT REPORT H1 2024/2025

PRELIMINARY REMARK

This report covers the first half of the 2024/2025 financial year, i.e. the reporting period from October 1, 2024 to March 31, 2025. The prior-year amounts stated below relate to the first half of the 2023/2024 financial year from October 1, 2023 to March 31, 2024. MeVis Medical Solutions AG prepared its annual financial statements for the 2023/2024 financial year in accordance with the provisions of the German Commercial Code (HGB) applicable to corporations and in compliance with the German Stock Corporation Act (AktG). These interim financial statements were also prepared on this basis.

FOUNDATIONS OF THE COMPANY

ORGANIZATION

MeVis Medical Solutions AG (hereinafter also referred to as "MMS AG", "MeVis" or the "Company") was founded in 1997 and commenced operations in 1998. 73.66 % of the share capital of MeVis Medical Solutions AG is currently held by Varex Imaging Deutschland AG, Willich. There is a control and profit and loss transfer agreement between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. Through Varex Imaging Deutschland AG, MeVis Medical Solutions AG thus belongs to the Varex Group under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

At the end of the 2023/2024 financial year, MeVis Medical Solutions AG held 49 % of MeVis BreastCare GmbH & Co. KG, Bremen (hereinafter also referred to as "MBC KG") as part of a joint venture with Varex Imaging Deutschland AG.

BRIEF OVERVIEW OF BUSINESS ACTIVITIES

MeVis Medical Solutions AG develops innovative software for recording, analyzing and evaluating image data and markets it to manufacturers of medical devices, providers of medical IT platforms and, to a lesser extent, directly to clinical end customers.

The clinical focus is on image-based early detection and diagnosis of epidemiologically significant diseases, such as breast, lung and liver diseases. The software solutions support many of the imaging procedures used. These include not only X-ray-based radiography procedures such as computed tomography, mammography or digital tomosynthesis, but also magnetic resonance imaging, digital sonography and the simultaneous use of several procedures (multimodality). MeVis supplies technologies and software applications for global market leaders in the medical sector that meet these companies' requirements for technology leadership and help them to expand their position.

In addition to the sale of software licenses and associated maintenance contracts, MeVis also offers software programming services for medical technology companies as development services. These include project processing by software development teams consisting of software developers, product and project managers, application specialists and test engineers. The teams support external customers in the development of software modules or applications and in the integration of new functions and new technologies, such as algorithms based on artificial intelligence. Services are also provided to clinical end customers. These include three-dimensional technical visualizations ("MeVis Distant Services"), interactive online training to improve clinicians' diagnostic skills and Internet-based special applications in teleradiology ("MeVis Online Services").

While in the early years of MeVis the focus was on image-based early detection and diagnosis of breast cancer, today MeVis uses the clinical expertise acquired, the know-how from the field of breast cancer, the innovative software technologies and the established partner network to successively develop the software solutions for new applications in other indications and diseases of other parts of the body.

ECONOMIC REPORT

BUSINESS PERFORMANCE

The Company's operating business consists of the development and sale of software licenses, the associated maintenance business, software programming for medical technology companies (development services) and the provision of services for technical visualizations (distant services) as well as online training.

At around 85% (previous year: 89%) of total sales, the software business, which includes products for the medical technology company Hologic, again accounted for the majority of the Company's total sales in this reporting period.

The first half of the 2024/2025 financial year was not entirely satisfactory for MeVis in terms of key financial figures. Although the Company continued to benefit from Hologic's good market position for breast cancer screening and also from the demand for lung cancer screening, we fell slightly short of our own license sales expectations.

EARNINGS SITUATION

In the first half of the year, the Company's revenue amounted to € 8,438 thousand (previous year: € 8,774 thousand). The sale of licenses accounted for 22% (previous year: 27%), maintenance revenue for 34% (previous year: 35%) and other revenue for 44% (previous year: 38%), which include services for and recharges to affiliated companies and the parent company. The deterioration in license revenue is attributable to the business with Hologic and the lack of license sales in lung cancer screening, while the slight deterioration in maintenance revenue results from business with various customers.

Other operating income amounted to € 1,233 thousand in the first half of the year (previous year: € 652 thousand). This mainly comprises income from exchange rate differences in the amount of € 1,188 thousand (previous year: € 531 thousand).

The cost of materials decreased to € 188 thousand (previous year: € 250 thousand). The Company's personnel expenses amounted to € 5,307 thousand in the first half of the year (previous year: € 5,073 thousand).

In the reporting period, the average number of permanent employees at the Company fell by 1 to 110.

Other operating expenses amounted to € 2,250 thousand in the reporting period (previous year: € 1,947 thousand). They comprise expenses from exchange rate differences of € 1,025 thousand (previous year: € 742 thousand), rental expenses of € 268 thousand (previous year: € 259 thousand), expenses for legal, consulting and auditing services of € 287 thousand (previous year: € 228 thousand), sales expenses of € 100 thousand (previous year: € 106 thousand), operating expenses of € 98 thousand (previous year: € 59 thousand) and other operating expenses of € 469 thousand (previous year: € 560 thousand).

Earnings before interest and taxes (EBIT) fell from € 2,092 thousand to € 1,853 thousand, mainly due to lower sales compared to the previous year, increased other operating income and higher personnel expenses.

Income from loans of financial assets amounted to € 550 thousand (previous year: € 258 thousand) and is attributable to interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of € 2,468 thousand (previous year: € 2,735 thousand).

Income taxes of € 64 thousand (previous year: € 74 thousand) were incurred in the past six months, therefore, taking into account the expenses from the profit to be transferred to Varex Imaging Deutschland AG in the amount of € 2,404 thousand (previous year: € 2,661 thousand), net income for the year amounted to € 0 thousand (previous year: € 0 thousand). It should be noted that the expense from the profit transfer does not legally arise until the end of the financial year.

NET ASSETS AND FINANCIAL POSITION

Total assets decreased to € 23,601 thousand (Sep. 30, 2024: € 26,484 thousand). Current assets decreased by € 2,943 thousand, while equity remained constant. Provisions decreased by € 593 thousand and liabilities decreased by € 2,164 thousand. Deferred income decreased by € 128 thousand.

The equity ratio increased to 76% (Sep. 30, 2024: 67%) due to the lower balance sheet total and constant equity, while the debt ratio fell accordingly to 24% (Sep. 30, 2024: 33%).

Current assets decreased by € 2,943 thousand to € 6,605 thousand as at the balance sheet date (Sep. 30, 2024: € 9,548 thousand). This is mainly due to the decrease in cash and cash equivalents (cash in hand, bank balances) from € 6,528 thousand to € 2,567 thousand.

The Company's equity remained constant at € 17,826 thousand (Sep. 30, 2024: € 17,826 thousand) and, in addition to the subscribed capital of € 1,820 thousand (Sep. 30, 2024: € 1,820 thousand), includes the capital reserve of € 11,461 thousand (Sep. 30, 2024: € 11,461 thousand) as well as the statutory revenue reserves of € 5 thousand (Sep. 30, 2024: € 5 thousand) and other revenue reserves of € 4,540 thousand (Sep. 30, 2024: € 4,540 thousand).

Provisions decreased by € 593 thousand compared to the previous year to € 1,707 thousand (Sep. 30, 2024: T€ 2.301). Pension provisions remained constant. Other provisions decreased to € 1,486 thousand, partly due to lower personnel provisions. Liabilities decreased by € 2,164 thousand to € 2,670 thousand (Sep. 30, 2024: € 4,834 thousand), mainly due to the reduction in liabilities to affiliated companies. Deferred income fell by € 126 thousand to € 1,397 thousand due to lower customer prepayments for services to be provided by the Company in the future compared to the previous year. The Company's cash and cash equivalents decreased by € 3,962 thousand to € 2,567 thousand in the first half of the year.

Overall, the net assets, financial position and results of operations remain satisfactory.

OPPORTUNITY AND RISK REPORT


There have been no significant changes to the Company's risk situation since the beginning of the financial year. The disclosures made in the opportunity and risk report in the financial statements at the end of the financial year as at September 30, 2024 therefore continue to apply.

FORECAST REPORT

At this point in time, we are sticking to our forecast: stable to slightly growing sales in the range of € 17.0 million to € 17.5 million are expected for the 2024/2025 financial year. In addition to stable sales with the customer Hologic, sales in the lung and liver segment are expected to increase slightly. We expect development services to remain stable. For earnings before interest and taxes (EBIT), we expect earnings of between € 3.5 million and € 4.0 million in the 2024/2025 financial year, assuming a stable exchange rate of 1.12 USD/EUR. The forecast stability or slight increase in revenue and the disproportionately low increase in personnel costs are the main drivers of the positive EBIT outlook.

As in the past reporting period, the Executive Board will regularly review its expectations over the course of the 2024/2025 financial year on the basis of current business developments.

Bremen, May 27, 2025



Marcus Kirchhoff
CEO

BALANCE SHEET

of MeVis Medical Solutions AG, Bremen, as of March 31, 2025

ASSETS (IN €)	Mar. 31, 2025	Sep. 30, 2024
A. Fixed assets		
I. Intangible assets		
Purchased concessions, industrial property rights and similar rights and assets as well as licenses to such rights and assets	0.00	0.00
II. Property, plant and equipment		
Operating and office equipment	285,638.76	315,234.14
III. Financial assets		
1. Shares in affiliated companies	299,805.00	299,805.00
2. Loans to affiliated companies	16,225,211.69	16,225,211.69
	16,525,016.69	16,525,016.69
	16,810,655.45	16,840,250.83
B. Current assets		
I. Receivables and other assets		
assets		
1. Trade receivables from goods and services trade receivables	2,549,815.43	2,242,558.44
2. Receivables from affiliated companies	689,379.12	522,447.01
3. Other assets	799,132.87	254,621.56
	4,038,327.42	3,019,627.01
II. Cash on hand, bank balances credit institutions		
	2,566,535.91	6,528,394.25
	6,604,863.33	9,548,021.26
C. Prepaid expenses and deferred charges	185,629.03	95,585.51
	23,601,147.81	26,483,857.60

LIABILITIES (IN €)	Mar. 31, 2025	Sep. 30, 2024
A. Equity		
I. Subscribed capital	1,820,000.00	1,820,000.00
II. Capital reserve	11,641,332.48	11,461,332.48
III. Retained earnings		
1. Legal reserve	5,000.00	5,000.00
2. Other retained earnings	4,539,688.30	4,539,688.30
	<u>4,544,688.30</u>	<u>4,544,688.30</u>
	<u>17,826,020.78</u>	<u>17,826,020.78</u>
B. Provisions		
1. Provisions for pensions and similar obligations obligations	220,960.00	247,540.00
2. Tax provisions	0.00	0.00
3. Other provisions	1,486,426.70	2,053,165.09
	<u>1,707,386.70</u>	<u>2,300,705.09</u>
C. Liabilities		
1. Advance payments received on orders	5,062.57	11,719.28
2. Liabilities from deliveries and services	83,040.21	85,509.17
3. Liabilities to affiliated companies	2,403,500.50	4,560,821.86
4. Other liabilities	178,827.96	175,992.72
	<u>2,670,431.24</u>	<u>4,834,053.03</u>
D. Prepaid expenses and deferred charges	<u>1,397,309.09</u>	<u>1,523,088.70</u>
	<u>23,601,147.81</u>	<u>26,483,857.60</u>

PROFIT AND LOSS ACCOUNT

of MeVis Medical Solutions AG, Bremen, for the period from October 1, 2024 to March 31, 2025

FIGURES IN €	2024/2025	2023/2024
1. Sales revenue	8,438,363.57	8,774,409.11
2. Other operating income	1,233,487.44	651,955.39
3. Cost of materials		
a) Expenses for purchased goods	33,608.13	34,506.89
b) Expenses for purchased services	154,688.42	215,639.75
	188,296.55	250,146.64
4. Personnel expenses		
a) Wages and salaries	4,434,751.26	4,249,997.73
b) Social security contributions and expenses for pensions and other employee benefits	871,826.17	823,363.13
	5,306,577.43	5,073,360.86
5. Amortization of intangible assets and depreciation of property, plant and equipment	73,882.29	63,320.55
6. Other operating expenses	2,250,284.98	1,947,141.62
7. Income from loans of financial assets fixed assets	549,928.63	528,336.59
8. Other interest and similar income	65,637.55	114,708.13
9. Taxes on income and earnings	64,875.44	74,046.26
10. Earnings after taxes	2,403,500.50	2,661,393.29
11. Profit to be transferred on the basis of a profit transfer agreement	2,403,500.50	2,661,393.29
12. Profit for the period	0.00	0.00

NOTES

to the half-year financial report of MeVis Medical Solutions AG, Bremen,
as of March 31, 2025

BASIC INFORMATION

GENERAL INFORMATION

MeVis Medical Solutions AG has its registered office at Caroline-Herschel-Strasse 1 in 28359 Bremen, Germany and is entered in the commercial register at Bremen Local Court (HRB 23791 HB).

73.66 % of the share capital of MeVis Medical Solutions AG is currently held by Varex Imaging Deutschland AG, Willich. There is a domination and profit and loss transfer agreement between Varex Imaging Deutschland AG, as the controlling company, and MeVis Medical Solutions AG, as the controlled company. Through Varex Imaging Deutschland AG, MeVis Medical Solutions AG thus belongs to the Varex Group under the management of Varex Imaging Corporation, Salt Lake City, Utah, USA.

MeVis Medical Solutions AG has prepared its annual financial statements for fiscal year 2023/2024 in accordance with the provisions of the German Commercial Code (HGB) applicable to corporations and in compliance with the German Stock Corporation Act (AktG). These interim financial statements were also prepared on this basis. These interim financial statements were neither reviewed nor audited in accordance with Section 317 HGB.

ACCOUNTING AND VALUATION METHODS

In preparing the interim financial statements and determining the comparative figures for the previous year, the same accounting policies were applied as in the 2023/2024 annual financial statements. A detailed description of these methods is published in the notes to the 2023/2024 annual financial statements.

SELECTED NOTES TO THE BALANCE SHEET AND INCOME STATEMENT

1. RECEIVABLES AND OTHER ASSETS

Trade receivables amounted to € 2,550 thousand as at the reporting date (Sep. 30, 2024: € 2,243 thousand) and mainly relate to receivables from the customers Hologic, Intrasure and Varian Medical Systems. All receivables have a remaining term of up to one year.

Of the receivables from affiliated companies, € 92 thousand (Sep. 30, 2024: € 70 thousand) relate to trade with MeVis BreastCare GmbH & Co. KG and € 597 thousand (Sep. 30, 2024: € 452 thousand) to trade with Varex Imaging Deutschland AG, Willich and Varex Imaging Corporation, Salt Lake City, USA.

Other assets amounted to € 800 thousand as at the balance sheet date (Sep. 30, 2024: € 250 thousand). These relate to an interest receivable of € 550 thousand (Sep. 30, 2024: € 0 thousand) from the loan issued to Varex Imaging Deutschland AG and a rental deposit of € 250 thousand.

2. PROVISIONS

Other provisions amount to € 1,486 thousand (Sep. 30, 2024: € 2,053 thousand). Of these, € 418 thousand (Sep. 30, 2024: € 609 thousand) relate to outstanding invoices and € 318 thousand (Sep. 30, 2024: € 560 thousand) to bonus provisions, 353 thousand (Sep. 30, 2024: € 263 thousand) to provisions for vacation and overtime, € 249 thousand (Sep. 30, 2024: € 249 thousand) to provisions for guarantees and € 149 thousand (Sep. 30, 2024: € 305 thousand) to provisions for the 13th salary.

3. LIABILITIES

Trade payables decreased by € 2 thousand in the reporting period and amounted to € 83 thousand as at the reporting date. The liabilities to affiliated companies of € 2,404 thousand (Sep. 30, 2024: € 4,561 thousand) relate to the profit transfer based on the existing control and profit transfer agreement with Varex Imaging Deutschland AG. The liability does not legally arise until the end of the 2024/2025 financial year.

4. ACCRUALS AND DEFERRED INCOME

This item includes deferred revenue components from multi-component contracts that have already been paid but not yet realized. In addition, payments received from maintenance contracts are deferred if the corresponding maintenance service has not yet been performed.

5. SALES REVENUE

Sales revenues are broken down into the following types of revenue:

FIGURES IN THOUSANDS OF €	01.10.2024 - 31.03.2025	01.10.2023 - 31.03.2024
Services (consulting and training)	3,701	3,338
Maintenance (software service contracts)	2,910	3,106
Software and licenses	1,827	2,330
	8,438	8,774

6. OTHER OPERATING INCOME

Other operating income amounted to € 1,233 thousand in the first half of the year (previous year: € 652 thousand). Of this, € 1,188 thousand (previous year: € 531 thousand) is mainly attributable to exchange rate differences. The exchange rate differences are due to the fact that the majority of services are invoiced in US dollars and liquidity is also held in US dollars. Due to the fact that the Company belongs to the Varex Imaging Group and in line with its corporate policy, no hedging transactions are concluded.

7. PERSONNEL EXPENSES

The average number of employees was 114 (same period in the previous year: 116), of which 110 are permanent employees (same period in the previous year: 111). This corresponds to an average of 100 full-time equivalents (prior-year period: 101).

8. OTHER OPERATING EXPENSES

Other operating expenses amounted to € 2,250 thousand in the reporting period (previous year: € 1,947 thousand). They comprise expenses from exchange rate differences amounting to € 1,025 thousand (previous year: € 742 thousand), rental expenses of € 268 thousand (previous year: € 259 thousand), expenses for legal, consulting and auditing services of € 287 thousand (previous year: € 228 thousand), sales expenses of € 100 thousand (previous year: € 106 thousand), operating expenses of € 98 thousand (previous year: € 59 thousand) and other operating expenses of € 469 thousand (previous year: € 560 thousand).

9. RELATIONSHIPS WITH RELATED PARTIES

The Company conducts transactions with related parties, which are explained below. These are part of the ordinary business activities and are treated as transactions with third parties.

Related parties include the jointly controlled companies MBC KG, Varex Imaging Deutschland AG and, via these, the affiliated companies of the Varex Group as well as the Executive Board and the Supervisory Board and their close relatives.

The following receivables, liabilities, expenses and income of the Company relate to related parties:

FIGURES IN THOUSANDS OF €	2024/2025
Parent company	
Receivables (from loans granted)	16,225
Receivables (from services)	104
Interest receivables (from loans granted)	550
Liabilities (from profit transfer agreement)	2,403
Income (mainly services and interest income)	1,073
Expenses (from profit transfer agreement)	2,403
Other affiliated companies	
Receivables (from services)	586
Income (mainly services and interest income)	1,430

SUPPLEMENTARY REPORT

There were no business transactions of particular significance for the Company after the balance sheet date.

ASSURANCE OF THE LEGAL REPRESENTATIVE

"To the best of my knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim financial statements of MeVis Medical Solutions AG give a true and fair view of the assets, liabilities, financial position and profit or loss of MeVis Medical Solutions AG, and the interim management report includes a fair review of the development and performance of the business and the position of MeVis Medical Solutions AG, together with a description of the principal opportunities and risks associated with the expected development of MeVis Medical Solutions AG for the remaining months of the financial year."

Bremen, May 27, 2025

MeVis Medical Solutions AG



Marcus Kirchhoff
CEO

DISCLAIMER

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that are based on management's current estimates of future developments. Such statements are subject to risks and uncertainties that are beyond MeVis Medical Solutions AG's ability to control or estimate precisely, such as future market and economic conditions, the behavior of other market participants, the ability to successfully integrate acquired businesses and the actions of government regulators. Should any of these or other uncertainties and imponderables materialize, or should the assumptions on which these statements are based prove incorrect, actual results may differ materially from those expressed or implied by such statements. MeVis Medical Solutions AG does not intend or assume any obligation to update any forward-looking statements to reflect events or developments after the date of this report.

DEVIATIONS FOR TECHNICAL REASONS

For technical reasons (e.g. conversion of electronic formats), there may be differences between the accounting documents contained in this financial report and those submitted to the Federal Gazette. In this case, the version submitted to the Federal Gazette is the binding version.

The financial report is also available in English; in the event of deviations, the German version takes precedence over the English translation.

The financial report is already available for download on the Internet at <http://www.mevis.de/de/investor-relations/finanzberichte/>

MeVis Medical Solutions AG

Caroline-Herschel-Str. 1
28359 Bremen
Germany

Phone +49 421 22495 0
Fax +49 421 22495 999
info@mevis.de

www.mevis.de